

# Post Tympanostomy Tube Otorrhea

Peter S Roland MD



## Incidence of PTTO

- 30% - 50% of patients suffer at least one otorrhea episode while the tube is in place<sup>1,2</sup>
- 10% - 20% of patients suffer from otorrhea within two weeks after tube placement<sup>1</sup>
- 22% of patients reported multiple episodes of acute otorrhea with 9% having 3 or more discrete bouts<sup>3-5</sup>

1. Lee D, et al., *Otolaryngol Head Neck Surg*. In press.  
2. Smelt GJ, et al. *J Laryngol Otol* 1984;98:243-245.

3. Mandel EM, et al., *Ann Otol Rhinol Laryngol*. 1994;103:7113-718  
4. McLelland CAI. *Arch Otolaryngol* 1980;106:97-99.  
5. Herzon FS. *Arch Otolaryngol*. 1980;106:645-647.

## Etiology

- Positive culture @ insertion
- Recurrent OM was indication
- Rhinitis--viral/AR
- NOT surface swimming!!




Microbiology of AOM  
with a tympanostomy tube

## Subjects & Methods


- 1309 isolates from 956 subjects recruited to 3 clinical trials
- Ages: 6 months -12 years
- Duration of drainage < 3weeks
- > 3 weeks from insertion of TT
- Cultures from lumen of TT
- Subspecies ID using phenotypic & DNA based characterization (Ribotyping & 16 S sequencing)

## Age breakdown




Roland *et al* Laryngoscope 2005

## Bacteriologic overview



Roland *et al* Laryngoscope 2005

## Most common isolates



# Traditional AOM pathogens


Acute Otitis Media With Tympanostomy Tubes (AOMT) Caused by *H. influenzae* and *S. pneumoniae* as Function of Subject Age

	0-3yrs (n=662)	3-5yrs (n=220)	6-12 yrs (n=114)
Subjects w <i>S pneumoniae</i>	26% (161)	11% (25)	8% (9)
Subjects w <i>H influenzae</i>	19% (118)	4% (8)	2% (2)
Subjects w <i>M catarrhalis</i>	6% (41)	4% (9)	2% (2)


# Fungal organisms

	AOMT		
<i>Candida</i> sp	<b>5.3%</b> N=58		
<i>Aspergillus</i> sp	0.2% N=2		


# Candida



# “No Growth” -- Age




# “No Growth” --Season



# Current Otic Treatment Issues

## Most Commonly Prescribed AOMT Treatments



👂 **78%** of AOMT patients were treated with systemic antibiotics

-N= 46,056 tube recipients  
 -10,328 AOMT Patients  
 -18,077 AOMT Rx

Source: July 2002 - May 2003 Verispan Medical and Prescription data retrospective analysis

# AOMT Treatment

- Topical Antibiotic drops
  - Aminoglycoside not recommended
    - Ototoxicity
    - Sensitization
    - efficacy
- Assure delivery
  - Aural toilet
  - irrigation

**Why topical  
instead of systemic  
as 1st line ??**



# ADVANTAGES



- Delivery of high concentration
  - Increased efficacy
  - minimize emergence of resistant strains
- Minimal systemic effect
- Low cost
- Alter local micro-environment

## Antibiotic Concentrations

- 3-5 GTTS dose of a 0.3% solution is only 90 $\mu$ g - 150mcg but at a concentration of **3000mcg/ml** which exceeds the MIC of any known relevant pathogen.
- Compare with typical ME fluid levels achievable with systemic antibiotics:
  - Amoxicillin (90-100mg/kg/d)      **8-10mcg/ml**
  - Cefuroxime (Ceftin®)      **2-4mcg/ml**
  - Ceftriaxone (Rocephin®)      **25-30mcg/ml**


# DISADVANTAGES

- Local discomfort
  - pH
  - alcohol
  - temperature
- Topical sensitization
- Minimal systemic effect
- Require direct contact!!



## Topical vs Systemic


- N = 30/30
  - 40 pts treated previously with systemics
  - eradication rates
- |              | Erad | Persis |
|--------------|------|--------|
| <b>Gent</b>  | 43%  | 57%    |
| <b>Cipro</b> | 85%  | 17%    |
- none of the persistent organisms were resistant to either medicine



Esposito et al: Arch Otolaryngol HNS 1992

# Topical vs Oral

- N =20/20/20
- TREATMENT:
  - either Cipro PO 250mg BID or
  - Cipro GTTS 250µg/ml BID or
  - both
- Clinical & bacteriological cure rates were statistically significantly higher for the topically treated groups ( $P < 0.05$ )



Esposito *et al*: Arch Otolaryngol HNS 1990

# Antibiotic Delivery

From otorrhea fluid:

@1/2 - 2 hrs:

- N=17
- Mean: 1,569 mcg/g
- Range: 388-2849

@3-5 hrs:

- N=16
- Mean: 262 mcg/g
- Range: 81-1099


• *Mucosa*

- N=16 @ ≈1hr
- Mean: 31.7 mcg/g
- Range: 0-602

Ohyama *et al*: Arch Otolaryngol HNS 1999



# Tube Otorrhea

- N=140/146
- 1-12 yrs.
- Patent tube with otorrhea < 3 wks.
- All with *P. aerug* as sole isolate were excluded!




**Goldblatt et al. *Int J Pediatr Otorhinolaryngol* 46(1998)**

# Steroids




**Roland et al *Laryngoscope* Dec 2003**

# Time to Cessation of Otorrhea



Roland *et al* Pediatrics Jan 2004

# Topical vs Amox/Clav



N=80 Ave age 1.88 yrs

Dohar *et al* Pediatrics 2006

# Why Do We Fail?

## Persistent Otorrhea

**Subspecies identification using genetic analysis (ribotyping) of organisms cultured from failures demonstrated:**

- 34/800 children had persistent otorrhea
- 17/34 were persistent infection
- 17/34 were re-infection

## Failure of delivery

- Administration
  - Wrong route
  - Compliance
  - Technique
    - Tragal pump
- Anatomic
  - mucopus
  - Granulation tissue
  - Mucosal edema
  - Sequestered nidus



## Aural Toilet

- **Aural Toilet**
  - **Dry mopping**
  - **Home irrigations**
  - **Office suction**




# Control of Granulation Tissue

- *Anti-infectives*
- *Steroids*
  - limited “hard” data but opinion is overwhelming
  - more potent steroid preferred
- *Cautery*
  - silver nitrate most common
  - can produce injury



## % Free of Granulation Tissue

**N = 92**






# Control of Granulation Tissue

- *Debridement*
  - Office
    - especially polyps in the EAC
    - avoid avulsion, sharp techniques will avoid injury
  - Operative
    - middle ear and mastoid

# Re-infection

- From EAC
  - Water ??
- ET reflux
  - Lack of middle ear “pillow”
  - Disease of NP, sinuses, adenoids?
- Immunologic defect

# Tympanostomy tube



**Tympanostomy tube**

**Chinchilla ME**

Post JC Laryngoscope 2001

## Remove Tube ?

- Topical antibiotics
  - Drops/powders
  - Direct instillation
- ? Systemic antibiotics
  - Oral quinolones
  - IV aminoglycosides
  - IV cephalosporins



# Questions?

## Alters environment

- Concentration of enzymes
  - Can erode mucosa/bone.
- Concentration of metabolic products
- Protection from fluctuations in environment
- Protection from antibiotics
  - Altered metabolism
  - Glycocalyx excludes antibiotics
  - Concentrates protective factors

**CDC has recently stated that  
65% of all clinical infections  
are caused by biofilms,  
including Otitis Media !!**

## Clinical

- Tympanostomy tubes
  - C. Post, Berry, Biedlingmaier and others have clearly shown that biofilms grow on tubes using SEM and fluorescent techniques
  - Surface characteristics of tube important
  - Post tympanostomy otorrhea one cause of CSOM

